An interventional study of Intervention bundle comprising increased awareness, early diagnostics, and early treatment to improve HF prognosis. in Heart Failure (HF), sponsored by University Hospital, Basel, Switzerland. Recruiting at 21 sites in 9 countries. Open to participants aged 65 Years and older. Per ClinicalTrials.gov, last updated 2026-07-28.
Sponsored by University Hospital, Basel, Switzerland · Not applicable, Interventional, and Diagnostic
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 11 studies in Heart Failure by University Hospital, Basel, Switzerland — 2 open to participants now, 3 under way, none of them phase 3. Heart Failure · University Hospital, Basel, Switzerland.
Among the 11 studies in Heart Failure by University Hospital, Basel, Switzerland, this one is one of 2 that started in 2025, is one of 5 with no phase, and was the 11th registered.
6,340 studies on the registry are indexed under Heart Failure; 1,397 are open to participants now.
Browse Heart Failure studies →2 of the 11 studies in Heart Failure by University Hospital, Basel, Switzerland are open now, in 9 countries. Recruiting first, the newest first:
University Hospital, Basel, Switzerland · Sites in Switzerland
Ages 18+
By country, each count listing its studies:
Of the 968 Heart Failure studies recruiting now, 691 (71%) set no upper age limit and 90 (9%) stop at 75 or younger; 64 take children under 18; 97 take healthy volunteers.
This study: 65 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
11 studies; the count open now beside each. This study's row is marked.
First in 2004; this study’s year is marked. 2 started in 2025.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 18,000 is above the median of 76 across 4,053 interventional studies indexed under Heart Failure.
Median enrollment 202 across the 8 interventional studies, 350 across the 3 observational. Of the 7 that completed or were terminated, 0 (0%) have results posted.
This tab as a report to print or save as PDF → With an account.
University Hospital, Basel, Switzerland is the lead sponsor of 990 studies on the registry; 189 are open to participants now.
1 of the studies in Heart Failure by University Hospital, Basel, Switzerland that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT06942221University Hospital, Basel, SwitzerlandDigital Solutions in Heart Therapy (DIGNITY) | 2026-12-31 |
Add it to your calendar (.ics) → With an account.
Among the 11 studies in Heart Failure by University Hospital, Basel, Switzerland, from their registry updates:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
Heart failure (HF) occurs when the heart is no longer able to pump blood effectively throughout the body. This leads to symptoms that gradually worsen over time and are often mistaken for normal signs of aging. Because of its insidious onset, early detection is challenging. Both patients and healthcare professionals are often insufficiently aware of the early signs and symptoms of HF, resulting in delayed diagnosis. Consequently, timely initiation of treatments that could slow disease progression, improve quality of life, and reduce hospitalizations is often missed. Although a simple blood test measuring NT-proBNP levels can facilitate the early diagnosis of HF, it is not routinely used in clinical practice.
The aim of this study is to evaluate whether a combined strategy for the early diagnosis and treatment of HF can reduce hospitalizations. This strategy includes:
The researchers will assess whether this strategy effectively reduces hospitalizations due to acute heart failure over an 18-month follow-up period.
Heart failure (HF) is a significant global health issue, affecting approximately 64 million individuals worldwide and resulting in over a million hospitalizations annually in Europe and the US. This imposes substantial healthcare costs exceeding $100 billion yearly, with about 70% attributed to acute hospitalizations. The aging population contributes to a rising burden, as HF is often diagnosed late, even in well-funded healthcare settings. Recent insights from studies, including the ongoing BASEL VIII study, challenge the assumption that undetected HF is primarily a failure to detect HF in primary care, revealing a high prevalence of undetected HF even among patients treated by cardiologists. This research initiative revealed that among patients ≥ 65 years, only 3% had known HF, while 29% had undetected HF. Similar observations were also noted in various high-risk settings worldwide, suggesting a surprisingly high rate of undetected HF in clinical practice. Late diagnosis is driven by gradual symptom development, non-specific symptoms often attributed to aging, insensitive clinical signs, and inadequate utilization of B-type natriuretic peptide (BNP) or N-terminal pro-B-type natriuretic peptide (NT-proBNP) testing, the recommended tools for HF diagnosis. The misconception that HF competes with other cardiac diagnoses, rather than complementing them, further contributes to delayed diagnosis. Emerging evidence supports a strategy combining increased awareness, active surveillance using NT-proBNP testing for early HF diagnosis, and prompt treatment with approved evidence-based therapies to reduce HF hospitalizations. However, such intervention bundles are not systematically applied, as no randomized controlled trial (RCT) has ever investigated the efficacy of such structured interventions on hard outcomes. This research initiative aims to assess the effectiveness of an intervention bundle comprising increased awareness, early diagnostics, and early treatment to improve HF prognosis. The study aims to fill critical gaps and evaluate patient-centred outcomes, including hospitalization for acute HF, and health economic implications by using routine clinical data and the standard operating procedures as part of routine clinical practice in the participating sites. By addressing these challenges, the initiative seeks to enhance patient outcomes, reduce the burden on healthcare systems, and contribute to advancing HF care. The bundle intervention, comprising an educational program, guidelines-directed diagnostics, and guidelines-supported management, represents a proactive implementation of best clinical practice. As this proactive approach is not routinely implemented in real-world clinical dynamics, this study primarily focuses on accompanying the implementation of the intervention bundle and contributing valuable data regarding its efficacy. At the same time, the intervention is expected to offer a number of potential benefits for the patients, their health care providers, and the society in general. This will be achieved by a better understanding of the HF problem among patients and medical staff, better adherence to guidelines-supported best clinical practices, and the potential avoidance of hospitalisations due to acute HF.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Elective percutaneous coronary intervention* (PCI), pulmonary vein isolation* (PVI), pacemaker implantation* (PM, no cardiac resynchronisation), transcatheter aortic valve intervention* (TAVI), major non-cardiac surgery* or presenting with tachyarrhythmia to the emergency department (ED) (without a diagnosis of HF within 24h).
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².
Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.
Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.
GFR and eGFR (kidney filtering)
GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².
Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Metastases
Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hypersensitivity
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Excipients
The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Intervention
Other: Intervention bundle comprising increased awareness, early diagnostics, and early treatment to improve HF prognosis.
The study aims to fill critical gaps and evaluate patient-centred outcomes, including hospitalization for acute HF, and health economic implications by using routine clinical data and the standard operating procedures as part of routine clinical practice in the participating sites.
Acute HF event
Time from the index procedure to an acute HF event or follow-up date, together with binary variable indicating the occurrence of an acute Hf event. Acute HF event during index hospitalization is defined as acute HF severe enough to require admission to an intensive/intermediate care unit, non-invasive ventilation, or treatment with at least 40mg furosemide IV.
Time frame: 18 months after intervention
CV death or acute HF event
Time from index hospitalisation to acute HF event, CV death or follow-up date, together with binary variable indicating the occurrence of acute HF event or CV death.
Time frame: 18 months
Hierarchical ordinal composite of CV death, acute HF hospitalization, acute HF during index hospitalization, and no event
Hierarchical ordinal composite of CV death, acute HF hospitalization, acute HF during index hospitalization, and no event (analyzed using the Finkelstein-Schoenfeld win ratio framework. Ties will be resolved according to the predefined event hierarchy. The effect measure will be the win ratio with 95% confidence intervals and two-sided p-values).
Time frame: 18 months
All-cause death
Time from index hospitalisation to hospitalization for acute HF, death, or follow-up date, together with binary variable indicating the occurrence of hospitalization for acute HF or death.
Time frame: 18 months
Cardiovascular death
Time from index hospitalisation to CV death or follow-up date, together with binary variable indicating CV death.
Time frame: 18 months
All-cause hospitalizations
Time from index hospitalisation to hospitalization for acute HF, death, or follow-up date, together with binary variable indicating the occurrence of hospitalization for acute HF or death.
Time frame: 18 months
Changes in medical treatment between the index hospitalisation
Categorical variables indicating changes in specific medical treatments. Changes in medication list (dosage, active pharmaceutical ingredient) during the periods of 1) before index presentation until discharge and 2) after discharge from the index hospitalization up to the 18-month follow-up period measured from the time of the intervention
Time frame: 18 months
Change in kidney function
Standard blood tests obtained during routine clinical care like serum creatinine indicating changes in the kidney function.
Time frame: 18 months
Health economic outcomes: cost of patient management
Cost of patient treatment within 18 months after the index hospitalisation, from different perspectives: hospital real costs perspective, full institutional perspective (considering real costs and reimbursements), healthcare payer perspective.
Time frame: 18 months
Health economic outcome: cost-effectiveness in terms of cost per hospitalization for acute HF avoided
Cost of patient treatment within 18 months after the index hospitalisation and number of hospitalizations for acute HF within 18 months after the index hospitalisation.
Time frame: 18 months
Outcomes for implementation
Feasibility and Appropriateness of the implementation strategy according to Weiner et. al.
Time frame: 18 months
Prevalence of undetected / untreated / suboptimal treated HF patients overall and in the different medical settings
Continuous variable representing the proportion of patients in the entire study population, this includes patients as well with exclusions criteria.
Time frame: 18 months
Ratio between previously known and undetected HF overall and in the different medical settings, and the corresponding number needed to screen to detect one patient with undetected HF
Continuous variable representing the proportion of newly diagnosed HF patients to previously diagnosed HF cases again assed in the overall population, this includes patients as well with exclusions criteria.
Time frame: 18 months
Plan to share: Undecided
No publications or documents are linked to this record.
Started Dec 2025 (actual). Primary completion is estimated for Apr 2028, 28 months after the start.
Of 1,119 non-industry interventional studies with no phase under Heart Failure, half reached primary completion within 29 months of starting (the median), counting those still running; a quarter within 16 and three quarters within 50. This study's planned 28 months is close to that.
Counting every sponsor, half of 1,355 studies reached it within 31 months; a quarter within 16 and three quarters within 52.
How these figures are worked out, and which studies are left out of them.
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
University Hospital, Basel, Switzerland →